JAZZ vs LRMR
JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments. LRMR: Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the underlying protein deficiency in Friedreich's ataxia.
Side-by-side fundamentals
| Metric | JAZZ | LRMR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $255.43 | $3.83 | |
| Market cap as of 2026-08-01 | $15.9B | $397M | |
| P/E as of 2026-08-01 | 539.66 | n/a | |
| PEG as of 2026-08-01 | 65.11 | -0.05 | LRMR lower |
| Net margin as of 2026-08-01 | +0.7% | n/a | |
| Gross margin as of 2026-08-01 | +88.0% | n/a | |
| Operating margin as of 2026-08-01 | -0.8% | n/a | |
| ROE as of 2026-08-01 | +0.7% | -134.1% | JAZZ higher |
| ROA as of 2026-08-01 | +0.3% | -96.0% | JAZZ higher |
| Debt / equity as of 2026-08-01 | 1.18 | 0.00 | LRMR lower |
| Revenue growth (YoY) as of 2026-08-01 | +9.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.3% | n/a | |
| Beta as of 2026-08-01 | 0.37 | 0.75 | |
| 1-year return as of 2026-07-27 close | +116.0% | -1.3% | JAZZ higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.